Matches in Nanopublications for { ?s ?p ""Ranolazine extended-release tablets are contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions ( 7.1 Taking inducers of CYP3A [see Drug Interactions ( 7.1 With liver cirrhosis [see Use in Specific Populations (8.6 Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) ( 4 7.1 CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) ( 4 7.1 Liver cirrhosis ( 4 8.6"" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- association label ""Ranolazine extended-release tablets are contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions ( 7.1 Taking inducers of CYP3A [see Drug Interactions ( 7.1 With liver cirrhosis [see Use in Specific Populations (8.6 Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) ( 4 7.1 CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) ( 4 7.1 Liver cirrhosis ( 4 8.6"" assertion.